NICE OK for Braftovi skin cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Braftovi and Mektovi combination as an option for some people with melanoma.
Read More
Tag: mektovi
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
